The authors of this analysis suggested that this phenomenon in the SUSTAIN 6 study might be attributed to a rapid reduction in HbA1C during the initial 16 weeks in patients treated with Semaglutide and insulin, particularly those already suffering from retinopathy with poor glycemic control [7]. This evidence concerns the gene INS and retinal disorder.